[go: up one dir, main page]

BE2013C051I2 - - Google Patents

Info

Publication number
BE2013C051I2
BE2013C051I2 BE2013C051C BE2013C051C BE2013C051I2 BE 2013C051 I2 BE2013C051 I2 BE 2013C051I2 BE 2013C051 C BE2013C051 C BE 2013C051C BE 2013C051 C BE2013C051 C BE 2013C051C BE 2013C051 I2 BE2013C051 I2 BE 2013C051I2
Authority
BE
Belgium
Application number
BE2013C051C
Other languages
French (fr)
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26545273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C051(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BE2013C051I2 publication Critical patent/BE2013C051I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2013C051C 1999-09-16 2013-07-22 BE2013C051I2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP26185299 1999-09-16
JP2000130371 2000-04-28
PCT/JP2000/006258 WO2001019802A1 (fr) 1999-09-16 2000-09-13 Composes cycliques aromatiques azotes a six elements
EP00960979A EP1219609B1 (en) 1999-09-16 2000-09-13 Aromatic nitrogenous six-membered ring compounds

Publications (1)

Publication Number Publication Date
BE2013C051I2 true BE2013C051I2 (es) 2019-10-16

Family

ID=26545273

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C051C BE2013C051I2 (es) 1999-09-16 2013-07-22

Country Status (27)

Country Link
US (2) US6656935B2 (es)
EP (1) EP1219609B1 (es)
KR (1) KR100532546B1 (es)
CN (2) CN1374953A (es)
AR (1) AR025668A1 (es)
AT (1) ATE358670T1 (es)
AU (1) AU767558B2 (es)
BE (1) BE2013C051I2 (es)
BG (1) BG65453B1 (es)
BR (1) BRPI0014526C1 (es)
CA (1) CA2383466C (es)
CY (2) CY1106534T1 (es)
DE (1) DE60034239T2 (es)
DK (1) DK1219609T3 (es)
ES (1) ES2283315T3 (es)
FR (1) FR13C0050I2 (es)
HK (1) HK1044535A1 (es)
HU (1) HU225917B1 (es)
IL (2) IL148291A0 (es)
LU (1) LU92249I2 (es)
MY (1) MY123528A (es)
NO (2) NO322038B1 (es)
PT (1) PT1219609E (es)
RU (1) RU2233273C3 (es)
TR (1) TR200200701T2 (es)
TW (1) TWI258471B (es)
WO (1) WO2001019802A1 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20080027037A1 (en) * 2000-04-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Cyclic compounds
US7220736B2 (en) * 2000-04-28 2007-05-22 Tanabe Seiyaku Co., Ltd. Pyrimidine compounds
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
JP4588973B2 (ja) * 2000-09-06 2010-12-01 田辺三菱製薬株式会社 経口投与用製剤
ES2315308T3 (es) * 2000-09-20 2009-04-01 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de pirazina como moduladores de tirosina quinasas.
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
NZ527585A (en) 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
WO2003032997A1 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
DE60221627D1 (de) * 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US7176310B1 (en) * 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
AU2003223786A1 (en) 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2003101994A1 (en) * 2002-05-29 2003-12-11 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
JP2006509014A (ja) 2002-12-04 2006-03-16 ジーン ロジック インコーポレイテッド メラノコルチンレセプターの調節因子
AU2005238296A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
BRPI0610498A2 (pt) 2005-04-19 2010-06-22 Nycomed Gmbh uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080051413A1 (en) * 2006-08-25 2008-02-28 Kaohsiung Medical University Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance
CN101511364B (zh) 2006-09-07 2012-08-15 奈科明有限责任公司 用于糖尿病的治疗组合
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
MX2009013354A (es) 2007-06-04 2010-07-06 Univ Ben Gurion Compuestos de triarilo y composiciones que los contienen.
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
WO2009051112A1 (ja) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
EP2082772A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082768A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082771A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082766A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Blister Strip Coil Forming
EP2082767A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
AU2009225869B2 (en) * 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
US8354593B2 (en) * 2009-07-10 2013-01-15 Nanocomp Technologies, Inc. Hybrid conductors and method of making same
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
CN101798301A (zh) * 2010-04-13 2010-08-11 漆又毛 吡咯烷基嘧啶甲磺酰胺衍生物及制备方法
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
CN102372697A (zh) * 2010-08-19 2012-03-14 山东轩竹医药科技有限公司 取代的嘧啶类化合物
US8980904B2 (en) * 2011-07-21 2015-03-17 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
ES2641992T3 (es) 2012-08-14 2017-11-14 Xuanzhu Pharma Co., Ltd. Compuestos de pirimidina bicíclicos sustituidos
WO2014082737A1 (en) 2012-11-28 2014-06-05 Grunenthal Gmbh Specific carboxamides as kcnq2/3 modulators
MX2015006688A (es) * 2012-11-28 2015-08-10 Grünenthal GmbH Amino-arilcarboxamidas sustituidas como moduladores de kcnq2/3.
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
CN104059025B (zh) * 2013-03-20 2017-07-04 广州朗圣药业有限公司 一种用于制备阿伐那非的中间体及其制备方法
KR101749314B1 (ko) 2013-03-29 2017-07-03 수안주 파마 코포레이션 리미티드 비사이클릭-치환된 피리미딘 타입 pde-5 억제제의 프로드러그
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
WO2014187273A1 (zh) * 2013-05-23 2014-11-27 苏州明锐医药科技有限公司 阿伐那非的制备方法
CN103254179B (zh) * 2013-05-23 2014-09-10 苏州明锐医药科技有限公司 阿伐那非的制备方法
CN103265534B (zh) * 2013-05-23 2014-07-23 苏州明锐医药科技有限公司 阿伐那非的制备方法
CN103254180B (zh) * 2013-05-23 2014-07-23 苏州明锐医药科技有限公司 一种阿伐那非的制备方法
WO2015001567A1 (en) * 2013-07-01 2015-01-08 Msn Laboratories Private Limited Process for the preparation of (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2- (hydroxymethyl)-1-pyrrolidinyl]-n-(2-pyrimidinyl methyl-5-pyrimidine carboxamide
CN104557877B (zh) * 2013-10-28 2016-08-17 重庆安格龙翔医药科技有限公司 一种阿伐那非中间体及其制备方法和应用
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
CN104628708A (zh) * 2013-11-13 2015-05-20 北大方正集团有限公司 一种阿伐那非的晶型及其制备方法、用途和药物组合物
CN104628707A (zh) * 2013-11-13 2015-05-20 北大方正集团有限公司 一种阿伐那非的无定型及其制备方法、用途和药物组合物
CN104650045B (zh) * 2013-11-19 2017-04-19 苏州旺山旺水生物医药有限公司 阿伐那非的制备方法
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN103833736A (zh) * 2014-03-04 2014-06-04 北京澳合药物研究院有限公司 一种阿伐那非的制备方法
WO2015177807A1 (en) * 2014-05-22 2015-11-26 Wanbury Ltd. A process for the preparation of avanafil and its novel intermediates
CN104003981A (zh) * 2014-05-28 2014-08-27 河北康泰药业有限公司 阿伐那非的合成方法
CN104151299B (zh) * 2014-08-22 2017-03-08 北京科莱博医药开发有限责任公司 化合物、晶型化合物及其制备方法
CN104356115B (zh) * 2014-11-21 2016-08-24 齐鲁天和惠世制药有限公司 一种4-[(3-氯-4-甲氧基苄基)氨基]-2-[2-(羟甲基)-1-吡咯烷基]嘧啶-5-羧酸乙酯的制备方法
CN104530015B (zh) * 2014-12-10 2017-01-04 齐鲁天和惠世制药有限公司 一种阿伐那非的制备方法
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105924402A (zh) * 2016-05-06 2016-09-07 蚌埠中实化学技术有限公司 一种2-胺基甲基嘧啶盐酸盐的制备方法
WO2018011681A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
CN106496201A (zh) * 2016-10-31 2017-03-15 昆药集团股份有限公司 一种阿伐那非原料药的制备方法
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN107879986A (zh) * 2017-12-20 2018-04-06 重庆英斯凯化工有限公司 一种阿伐那非杂质的合成方法
CN108658872B (zh) * 2018-05-03 2021-06-22 无锡富泽药业有限公司 一种阿伐那非中间体的制备方法
CA3108551A1 (en) 2018-08-06 2020-02-13 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
CN109280049B (zh) * 2018-09-25 2021-02-02 重庆奥舍生物化工有限公司 一种医药化合物阿伐那非的合成方法
CN109776505B (zh) * 2019-03-14 2021-07-27 扬州市三药制药有限公司 一种阿伐那非的制备方法
CN110078713B (zh) * 2019-04-10 2021-06-04 北京精华耀邦医药科技有限公司 一种用于治疗男性勃起功能障碍的化合物
CN110117274A (zh) * 2019-05-08 2019-08-13 梯尔希（南京）药物研发有限公司 一种阿伐那非杂质的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1229413A (es) * 1967-06-14 1971-04-21
JPS5481299A (en) * 1977-12-09 1979-06-28 Daito Koeki Kk Preparation of 2,8-disubstituted-6-formyl-5,8-dihydro-5- oxopyrido 2,3-d pyrimidine derivative
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
WO1987004928A1 (en) * 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
EP0459918B1 (en) 1990-05-16 1995-12-06 Tomoegawa Paper Co. Ltd. Conductive substrate and printing media using the same
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5252604A (en) 1992-07-10 1993-10-12 Hoffmann-La Roche Inc. Compositions of retinoic acids and tocopherol for prevention of dermatitis
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
EP0640599B1 (en) * 1993-08-26 1998-03-04 Ono Pharmaceutical Co., Ltd. 4-Aminopyrimidine derivatives
EP0686625B1 (en) 1993-12-27 1999-05-26 Eisai Co., Ltd. Anthranilic acid derivative
EP0722936B1 (en) 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
KR100239800B1 (ko) 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
JP2000072751A (ja) * 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds

Also Published As

Publication number Publication date
LU92249I2 (fr) 2013-09-10
HUP0202795A2 (hu) 2003-02-28
EP1219609B1 (en) 2007-04-04
AU7311800A (en) 2001-04-17
LU92249I9 (es) 2019-01-03
CN102584799A (zh) 2012-07-18
TWI258471B (en) 2006-07-21
DE60034239D1 (de) 2007-05-16
BG65453B1 (bg) 2008-08-29
NO2013018I2 (no) 2015-01-12
ES2283315T3 (es) 2007-11-01
US6797709B2 (en) 2004-09-28
US20030032647A1 (en) 2003-02-13
ATE358670T1 (de) 2007-04-15
NO20021308L (no) 2002-04-24
RU2233273C2 (ru) 2004-07-27
DK1219609T3 (da) 2007-05-21
CY2013034I1 (el) 2016-04-13
US20030229095A1 (en) 2003-12-11
KR20020047170A (ko) 2002-06-21
HK1044535A1 (en) 2002-10-25
TR200200701T2 (tr) 2002-06-21
KR100532546B1 (ko) 2005-12-01
HUP0202795A3 (en) 2003-03-28
DE60034239T2 (de) 2007-12-27
FR13C0050I1 (es) 2013-09-27
CY1106534T1 (el) 2012-01-25
CY2013034I2 (el) 2017-03-15
MY123528A (en) 2006-05-31
RU2233273C3 (ru) 2019-07-17
BRPI0014526B8 (pt) 2017-03-21
CA2383466A1 (en) 2001-03-22
BRPI0014526C1 (pt) 2021-05-25
WO2001019802A1 (fr) 2001-03-22
BR0014526B1 (pt) 2013-09-10
EP1219609A4 (en) 2002-11-06
PT1219609E (pt) 2007-06-19
NO322038B1 (no) 2006-08-07
CA2383466C (en) 2009-08-25
US6656935B2 (en) 2003-12-02
HU225917B1 (en) 2007-12-28
BR0014526A (pt) 2002-06-18
EP1219609A1 (en) 2002-07-03
AU767558B2 (en) 2003-11-13
AR025668A1 (es) 2002-12-11
NO20021308D0 (no) 2002-03-15
BG106566A (en) 2003-02-28
NO2013018I1 (no) 2014-06-02
FR13C0050I2 (fr) 2014-04-11
IL148291A0 (en) 2002-09-12
CN1374953A (zh) 2002-10-16
IL148291A (en) 2006-10-05

Similar Documents

Publication Publication Date Title
BE2018C020I2 (es)
BE2015C057I2 (es)
BE2016C007I2 (es)
FR13C0050I1 (es)
JP2002534937A5 (es)
BE2008C046I2 (es)
BE1025464I2 (es)
JP2002514033A5 (es)
BRPI0017527B8 (es)
JP2001118249A5 (es)
JP2002539348A5 (es)
BRPI0001672A2 (es)
JP2002525444A5 (es)
JP2002522140A5 (es)
BRPI0001542A2 (es)
JP2002531906A5 (es)
HU0004966D0 (es)
BRPI0012675B8 (es)
BRPI0017522A2 (es)
BRMU7902607U2 (es)
GB9907418D0 (es)
GR20000200053U (es)
IN191700B (es)
CN3098953S (es)
BY5807C1 (es)